文献速递治疗药物监测与药物基因组学

英夫利昔单抗治疗药物监测在炎症性肠病中的新进展

New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
PubMed 文献 · Br J Clin Pharmacol · 2019-01-28

该研究回顾性纳入55例接受英夫利昔单抗维持治疗的炎症性肠病患者,采用液相色谱-串联质谱法测定谷浓度,通过ROC分析确定与生物学缓解相关的谷浓度阈值为6.2 mg/L,敏感性0.75、特异性0.61,为英夫利昔单抗个体化治疗提供新依据。

要点

  • 液相色谱-串联质谱法测定英夫利昔单抗谷浓度可用于炎症性肠病治疗药物监测。
  • 谷浓度6.2 mg/L与生物学缓解相关,敏感性0.75、特异性0.61。
  • 生物学缓解患者英夫利昔单抗谷浓度显著更高(P=0.038)。

核心结论

  • 液相色谱-串联质谱法测定英夫利昔单抗谷浓度并确定与生物学缓解相关的新阈值,是炎症性肠病患者英夫利昔单抗治疗个体化的新进展。

研究设计与样本

  • 回顾性研究,纳入55例接受英夫利昔单抗维持治疗的炎症性肠病患者,从病历收集人口学、生物学和临床数据,并测定血清英夫利昔单抗谷浓度。

主要发现

  • 英夫利昔单抗谷浓度范围为<1 mg/L至57.2 mg/L。
  • 生物学缓解患者英夫利昔单抗谷浓度更高(P=0.038)。
  • 谷浓度阈值6.2 mg/L与生物学缓解相关,敏感性0.75(95%CI 0.58-0.75),特异性0.61(95%CI 0.39-0.83)。

关键数值与推荐

  • 生物学缓解定义为C反应蛋白<5 mg/L且粪钙卫蛋白<150 μg/g。
  • 与生物学缓解相关的英夫利昔单抗谷浓度阈值为6.2 mg/L。

临床怎么用

  • 临床可参考液相色谱-串联质谱法测定的英夫利昔单抗谷浓度6.2 mg/L阈值评估炎症性肠病患者生物学缓解状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). However, the recommended target concentrations depend partly on the method used to quantify IFX. Since we recently developed a liquid chromatography-tandem mass spectrometry method to quantify IFX, we aimed to determine IFX trough concentrations (Cmin) associated with biological remission. METHODS: We retrospectively measured IFX Cmin in sera from 55 patients with IBD, on IFX maintenance therapy, and for whom demographic, biological and clinical data were collected from medical records. A threshold of IFX Cmin associated with biological remission (defined by C-reactive protein < 5 mg l-1 and faecal calprotectin <150 μg g-1 ) was determined using receiver operating characteristics analysis. RESULTS: IFX Cmin ranged from <1 mg l-1 to 57.2 mg l-1 . IFX Cmin were higher (P = 0.038) in patients with biological remission and a cut-off of IFX Cmin set to 6.2 mg l-1 was associated with biological remission (sensitivity = 0.75, 95% confidence interval 0.58-0.75; specificity = 0.61, 95% confidence interval 0.39-0.83). CONCLUSION: Liquid chromatography-tandem mass spectrometry measurement of IFX Cmin and the determination of a new threshold of IFX Cmin associated with biological remission are new steps towards IFX treatment personalization in patients with IBD.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Nemoz B, Ternant D, Bailly S, et al. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. Br J Clin Pharmacol. 2019. PMID: 30575085. doi:10.1111/bcp.13845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。